biotech — 2 leads
| Day | Found | Lead | Sector | Score | Catalyst | Src |
|---|---|---|---|---|---|---|
| Thu | Sep 24 | Celldex's hives drug won two Phase 3 trials decisively, and the stock fell 18% on two anaphylaxis cases On September 22, 2026 Celldex reported that barzolvolimab met every primary and key secondary endpoint in two Phase 3 trials of 1,939 patients with chronic spontaneous urticaria, with 45–54% of treated patients completely free of hives and itch at 24 weeks against 15–18% on placebo, but two life-threatening anaphylaxis cases in one dose group sent the shares down 18% in two sessions — the opportunity turns on whether the safety signal is a label problem or a commercial one, which the full safety tables and the 52-week data will settle. | biotech | 66 | Full 52-week EMBARQ data and a BLA submission planned for 2027; detailed safety tables not yet published as of September 24, 2026 | 5 |
| Mon | Aug 31 | An mRNA cancer vaccine passed Phase 3 for the first time A cancer vaccine custom-built for each individual patient worked in a large trial for the first time ever. Moderna already jumped on the news — but every single dose requires bespoke lab work, and the companies that would have to supply that are still priced for the post-COVID collapse. | biotech | 72 | Data release, then FDA filing | 3 |
Subscribe to get daily leads by email.